title: Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples.
authors.forename: Bernard
authors.initials: B
authors.lastname: Combe
authors.forename: Ronald
authors.initials: R
authors.lastname: van Vollenhoven
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D058990:Molecular Targeted Therapy / Q000379:methods*; D012219:Rheumatology / Q000639:trends*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; C561644:mavrilimumab; C575974:tabalumab; D008727:Methotrexate
keywords: DMARDs (biologic); Rheumatoid Arthritis; Treatment